Von Willebrand Disease News and Research

Latest Von Willebrand Disease News and Research

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

EMA expands administration options for Hizentra

EMA expands administration options for Hizentra

New smartphone app for patients with hemophilia and related bleeding disorders

New smartphone app for patients with hemophilia and related bleeding disorders

FDA expands Hizentra administration options for people with primary immunodeficiency

FDA expands Hizentra administration options for people with primary immunodeficiency

Japanese MHLW approves Hizentra for treatment of primary and secondary immunodeficiencies

Japanese MHLW approves Hizentra for treatment of primary and secondary immunodeficiencies

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Study sheds light on stem cell technique for treatment of common bleeding disorder

Study sheds light on stem cell technique for treatment of common bleeding disorder

GZS releases WebTracker-Hemophilia EHR patient registry system

GZS releases WebTracker-Hemophilia EHR patient registry system

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

Researchers uncover genetic causes of von Willebrand disease

Researchers uncover genetic causes of von Willebrand disease

Hemostatic testing may explain heavy menstrual bleeding

Hemostatic testing may explain heavy menstrual bleeding

CSL Behring rIX-FP granted Orphan Drug Designation to treat hemophilia B

CSL Behring rIX-FP granted Orphan Drug Designation to treat hemophilia B

FDA accepts CSL Behring’s 4-factor PCC BLA for standard review

FDA accepts CSL Behring’s 4-factor PCC BLA for standard review

Chinese sFDA approves Baxter's ADVATE to treat hemophilia A

Chinese sFDA approves Baxter's ADVATE to treat hemophilia A

CSL Behring commences C1-INH phase I/II study in hereditary angioedema

CSL Behring commences C1-INH phase I/II study in hereditary angioedema

CSL Behring commits donations to World Federation of Hemophilia GAP program

CSL Behring commits donations to World Federation of Hemophilia GAP program

CSL Behring initiates rVIIa-FP Phase I study in hemophilia A and B

CSL Behring initiates rVIIa-FP Phase I study in hemophilia A and B

Albumin best choice for prevention of circulatory dysfunction in cirrhotic patients

Albumin best choice for prevention of circulatory dysfunction in cirrhotic patients